General AML|FLT3

AACR 2017: Poster 3565/1 – The impact of germline FLT3 mutation on the prognosis of AML patients  

At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Monday 3rd April, a poster session titled “Growth Factor and Hormone Receptors as Therapeutic Targets” took place.

During this session, a poster (3561/1) titled “Recurrently detected germline mutation of FLT3 (D358V) associated with prevalence of hematopoietic malignancy and prognosis of AML patients” by Seulki Song and colleagues from the Cancer Research Institute, Seoul, Korea, was on display.

The authors performed a Whole Exome Sequencing (WES) on seventy-six AML patients’ (median age = 46 years) saliva samples.

The key results were:
  • Two regions of FLT3 mutations were detected; p.D835V/H and p.D358V
  • FLT3 p.D358V mutation frequency was significantly higher in AML patients than in general population; Odds Ratio (OR) = 8.499, P = 9.50E-07
  • In normal population (n = 2,504), from the 1,000 Genomes Project, 31% (n = 794) of Asian population carried the FLT3 D358V mutation, OR = 2.26, P = 0.07
  • FLT3 p.D358V patients had reduced Overall Survival (OS) compared to patients without FLT3 p.D358V; P = 0.03

In summary, germline mutation in FLT3 is strongly associated with the development of AML. Additionally, germline mutation and somatic mutation of FLT3 is significantly associated with prognosis of AML patients.

References
  1. Song S. et al. Recurrently detected germline mutation of FLT3 (D358V) associated with prevalence of hematopoietic malignancy and prognosis of AML patients [Poster]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [3565/1].